Synergy starts first Phase III study of constipation drug

US-based Synergy Pharmaceuticals has begun the first of two planned Phase III clinical studies to confirm the safety and efficacy of its lead GC-C agonist and once-daily oral treatment 'plecanatide', in adult patients with chronic idiopathic constipa…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news